CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞疗法：重编程患者免疫细胞以治疗癌症
英文原题：CAR T-cell therapy: Reprogramming patient's immune cell to treat cancer.
查看英文原题
CAR T-cell therapy: Reprogramming patient's immune cell to treat cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞疗法是癌症治疗领域的重要突破。尽管CAR-T 疗法已使部分B细胞白血病或淋巴瘤患者获得显著临床应答，但多种困难限制了其对实体瘤和血液系统恶性肿瘤的治疗效果。严重且危及生命的毒性、抗肿瘤效力不足、抗原逃逸、迁移受限以及肿瘤组织穿透能力有限，均是CAR-T 治疗成功的障碍。此外，CAR-T 细胞与宿主及肿瘤微环境之间的相互作用也会显著影响其活性。开发和实施这些疗法还需要复杂的专业团队。为应对上述重要挑战，需要创新方法和策略，以工程化改造出抗肿瘤活性更强、毒性更低的CAR-T 细胞。
展开英文摘要原文
Chimeric antigen receptor (CAR)-T cell therapy is a game changer in cancer treatment. Although CAR-T cell therapy has achieved significant clinical responses in specific subgroups of B cell leukaemia or lymphoma, various difficulties restrict CAR-T cell therapy's therapeutic effectiveness in solid tumours and haematological malignancies. Severe life-threatening toxicities, poor anti-tumour effectiveness, antigen escape, restricted trafficking, and limited tumour penetration are all barriers to successful CAR-T cell treatment.
Furthermore, CAR-T cell interactions with the host and tumour microenvironment have a significant impact on their activity.
Furthermore, developing and implementing these therapies necessitates a complicated staff. Innovative methodologies and tactics to engineering more potent CAR-T cells with greater anti-tumour activity and less toxicity are required to address these important difficulties.
论文信息
- 作者
- Mavi AK、Gaur S、Gaur G、Babita、Kumar N、Kumar U
- 第一作者单位
- Department of Pulmonary Medicine, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi 110007, India.India
- 通讯作者单位
- School of Biosciences, Institute of Management Studies Ghaziabad (University Courses Campus), NH09, Adhyatmik Nagar, Ghaziabad, Uttar Pradesh 201015, India. Electronic address: umeshkumar82@gmail.com.India
- 期刊
- Cellular signalling2023 May
- 原文标识
- PubMed 36822565 · DOI 10.1016/j.cellsig.2023.110638